An albumin-associated PLA2-like activity inactivates surfactant phosphatidylcholine secreted from fetal type II pneumocytes

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 301, Issue 6, 2011, Pages

  Damas, Jolanta E ^a   Cake, Max H ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

Lyso phosphatidylcholine; Phosphatidylcholine deacylation; Surfactant phospholipids

Indexed keywords

4 BROMOPHENACYL BROMIDE; ARISTOLOCHIC ACID; HUMAN SERUM ALBUMIN; PALMITOYLTRIFLUOROMETHYLKETONE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; EGTAZIC ACID; PHOSPHOLIPID; RECOMBINANT PROTEIN; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL CULTURE; FEMALE; GEL FILTRATION CHROMATOGRAPHY; LUNG ALVEOLUS CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THIN LAYER CHROMATOGRAPHY; ANIMAL; BLOOD; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; FETUS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PRIMARY CELL CULTURE; SECRETION; SERUM; WISTAR RAT;

ANIMALS; CELLS, CULTURED; EGTAZIC ACID; FETUS; HUMANS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPASES A2; PHOSPHOLIPIDS; PNEUMOCYTES; PRIMARY CELL CULTURE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SERUM; SERUM ALBUMIN;

EID: 82855181126     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00103.2011     Document Type: Article

References (71)

1. Albers JJ, Chen CH, Lacko AG. Isolation, characterization, and assay of lecithin-cholesterol acyltransferase. Methods Enzymol 129: 763-783, 1986.
2. Amirkhanian JD, Bruni R, Waring AJ, Taeusch HW. Inhibition of mixtures of surfactant lipids and synthetic sequences of surfactant proteins SP-B and SP-C. Biochim Biophys Acta 1096: 355-360, 1991.
3. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, Longacre S, Vargaftig BB, Brerzist G, Voelker DR, Wolf C, Touqui L. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest 102: 1152-1160, 1998.
4. Arbibe L, Vial D, Touqui L. Phospholipase A2 and acute respiratory distress syndrome. Prog Surg 24: 79-87, 1997.
5. Asokananthan N, Cake MH. Stimulation of surfactant lipid secretion from fetal type II pneumocytes by gastrin-releasing peptide. Am J Physiol Lung Cell Mol Physiol 270: L331-L337, 1996.
6. Attalah HL, Wu Y, Alaoui-El-Azher M, Thouron F, Kumaniv K, Wolf C, Brochard L, Harf A, Delclaux C, Touqui L. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J 21: 1040-1045, 2003.
7. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
8. Chotigeat U, Promwong N, Kanjanapattanakul W, Khorana M, Sangtawesin V, Horpaopan S. Comparison outcome of surfactant therapy in respiratory distress syndrome in two periods. J Med Assoc Thai 3: 109-114, 2008.
9. Cockshutt AM, Possmayer F. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins. Biochim Biophys Acta 1086: 63-71, 1991.
10. Cockshutt AM, Weitz J, Possmayer F. Pulmonary surfactant associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood protein in vitro. Biochemistry 29: 8424-8429, 1990.
11. Cott GR, Walker SR, Mason RJ. The effect of substratum and serum on lipid synthesis and morphology of alveolar type II cells in vitro. Exp Lung Res 13: 427-447, 1987.
12. Dobbs LG, Gonzalez R, Williams MC. An improved method for isolating type II cells in high yield and purity. Am Rev Respir Dis 134: 141-145, 1986.
13. Edelson JD, Vadas P, Villar J, Mullen JBM, Pruzanski W. Acute lung injury induced by phospholipase A2. Structural and functional changes. Am Rev Respir Dis 142: 1102-1109, 1991.
14. Elsbach P, Pettis P. Phospholipase activity associated with serum albumin. Biochim Biophys Acta 296: 89-93, 1973.
15. Fernsler JG, Zasadzinski JA. Competitive adsorption: a physical model for lung surfactant inactivation. Langmuir 25: 8131-8143, 2009.
16. Finkelstein JN, Maniscalco WM, Shapiro D. Properties of freshly isolated type II epithelial cells. Biochim Biophys Acta 762: 398-404, 1983.
17. Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G. Artificial pulmonary surfactant inhibited by proteins. J Appl Physiol 62: 429-437, 1987.
18. Galani V, Tatsaki E, Bai M, Kitsoulis P, Lekka M, Nakos G, Kanavaros P. The role of apoptosis in the pathophysiology of Acute Respiratory Distress Syndrome (ARDS): an up-to-date cell-specific review. Pathol Res Pract 206: 145-150, 2010.
19. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta 1408: 79-89, 1998.
20. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 13: 1455-1476, 1999.
21. Gross L, Wilson CM, Ingleson LD, Brehier A, Rooney SA. The influence of hormones on the biochemical development of fetal rat lung in organ culture: I. Estrogen. Biochim Biophys Acta 575: 375-383, 1979.
22. Grossmann G, Tashiro K, Kobayashi T, Suzuki Y, Matsumoto Y, Waseda Y, Akino T, Curstedt T, Robertson B. Experimental neonatal respiratory failure induced by lysophosphatidylcholine: effect of surfactant treatment. J Appl Physiol 86: 633-640, 1999.
23. Gunther AD, Valmrath R, Grimminger F, Seeger W. Alteration of pulmonary surfactant in ARDS-pathogenetic role and therapeutic perspectives. In: Acute Respiratory Distress Syndrome: Cellular and Molecular Mechanisms and Clinical Management. New York: Plenum, 1998, p. 97-106.
24. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of bronchoalveolar lavage phospholipids, surface activity, and plasma myoinositol. J Clin Invest 70: 673-683, 1982.
25. Hite RD, Seeds MC, Safta AM, Jacinto RB, Gyves JI, Bass DA, Waite BM. Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A2-mediated surfactant dysfunction. Am J Physiol Lung Cell Mol Physiol 288: L618-L624, 2005.
26. Holm BA, Enhoring G, Notter RH. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 49: 49-55, 1988.
27. Holm BA, Notter RH, Frankelstein JN. Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids. Chem Phys Lipids 38: 287-298, 1985.
28. Holm BA, Wang WD, Notter RH. Multiple mechanisms of lung surfactant inhibition. Pediatr Res 46: 85-93, 1999.
29. Horigome K, Hayakawa M, Inoue K, Nojima S. Purification and characterization of phospholipase A2 released from rat platelets. J Biochem 101: 625-631, 1987.
30. Hudson L, Hay FC. Practical Immunology. Oxford, UK: Blackwell Scientific, 1976.
31. Iwanicki JL, Lu KW, Taeusch HW. Reduction of phospholipase A2 inhibition of pulmonary surfactant with hyaluronan. Exp Lung Res 36: 167-174, 2010.
32. Jain SK, Diaz JJ. Plasma lecithin-cholesterol acyltransferase activity and cholesterol and phospholipid levels in premature newborn infants. Biochim Biophys Acta 1086: 225-229, 1991.
33. Jobe AH, Ikegami M. Lung development and function in preterm infants in the surfactant treatment era. Annu Rev Physiol 62: 825-846, 2000.
34. Jorgensen KM, Felberg S, Berge RK, Laegreid A, Johansen B. Platelet activating factor stimulates arachidonic fatty acid release in differentiated keratinocytes via arachidonyl non-selective phospholipase A2. Arch Dermatol Res 302: 221-227, 2010.
35. Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, Bonventre JV. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 269: L109-L118, 1995.
36. Kim YL, Im YJ, Ha NC, Im DS. Albumin inhibits cytotoxic activity of lysophosphatidylcholine by direct binding. Prostaglandins Other Lipid Mediat 83: 130-138, 2007.
37. Lachmann R, Eijking EP, So KL, Gommers D. In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function. Intensive Care Med 20: 6-11, 1994.
38. Langton SR, Dench J. Phospholipase A2 is associated with albumin in patients with acute pancreatitis. Clin Chim Acta 203: 249-258, 1991.
39. Lewis JE, Veldhuizen R. The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol 65: 613-642, 2003.
40. Lindahl M, von Schenck H, Tagesson C. Isolation and characterization of phospholipase A2 from rat lung with affinity chromatography and two-dimensional gel electrophoresis. Biochim Biophys Acta 1005: 282-288, 1989.
41. Liu L. Regulation of lung surfactant secretion by phospholipase A2. J Cell Biochem 72: 103-110, 1999.
42. Longo WE, Grossmann EM, Erikson B, Panesar N, Mazurski JE, Kaminski DL. The effect of phospholipase A2 inhibitors on proliferation and apoptosis of murine intestinal cells. J Surg Res 84: 51-56, 1999.
43. Lu KW, Goerke J, Clements JA, Taeusch HW. Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 58: 206-210, 2005.
44. Lu Q, Zhang M, Girardi C, Bouhemad B, Kesecioglu J, Rouby JJ. Computed tomography assessment of exogenous surfactant-induced lung reaeration in patients with acute lung injury. Crit Care 14: R135, 2010.
45. McIntyre RC, Pulido EJ, Bensard DD, Shames BD, Abraham E. Thirty years of clinical trials in acute respiratory distress syndrome. Crit Care Med 28: 3314-3331, 2000.
46. Merzouk H, Lamri MY, Meghelli-Bouchenak M, Korso N, Prost J, Belleville J. Serum lecithin: cholesterol acyltransferase activity and HDL2 and HDL1 composition in small for gestational age newborns. Acta Paediatr 86: 528-532, 1997.
47. Nakos G, Pneumatikos J, Tsangaris I, Tellis C, Lekka M. Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am J Respir Crit Care Med 155: 945-951, 1997.
48. Niewoehner DE, Rice K, Sinha AA, Wangensteen D. Injurious effects of lysophosphatidylcholine on barrier properties of alveolar epithelium. J Appl Physiol 63: 1979-1986, 1987.
49. Notter RH, Schwan AL, Wang Z, Waring AJ. Novel phospholipaseresistant lipid/peptide synthetic lung surfactants. Mini Rev Med Chem 7: 932-944, 2007.
50. Perez-Gil J, Keough KMW. Interfacial properties of surfactant proteins. Biochim Biophys Acta 1408: 203-217, 1998.
51. Petrovic N, Grove C, Langton PE, Misso NLA, Thompson PJ. A simple assay for a human serum phospholipase A2 that is associated with high-density lipoproteins. J Lipid Res 42: 1706-1713, 2001.
52. Piknova B, Schram V, Hall SB. Pulmonary surfactant: phase behavior and function. Curr Opin Struct Biol 12: 487-494, 2002.
53. Reynolds LJ, Hughes LL, Dennis EA. Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate reader. Anal Biochem 204: 190-197, 1992.
54. Sarrasague MM, Cimato A, de Celis ER, Facorro G. Influence of serum protein and albumin addition on the structure and activity of an exogenous pulmonary surfactant. Respir Physiol Neurobiol 175: 316-321, 2011.
55. Scott JE. The role of sera, growth factors, and hormones in the in vitro production of disaturated phosphatidylcholine and propagation of undifferentiated type II alveolar cells from the fetal rabbit lung. Exp Lung Res 12: 181-194, 1987.
56. Seeger W, Stohr G, Wolf HR, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 58: 326-338, 1985.
57. Seidner SR, Jobe AH, Ikegami M, Pettenazzo A, Priestley A, Ruffini L. Lysophosphatidylcholine uptake and metabolism in the adult rabbit lung. Biochim Biophys Acta 961: 328-336, 1988.
58. Sen N, Cake MH. Enhancement of disaturated phosphatidylcholine synthesis by epidermal growth factor in cultured fetal lung cells involves a fibroblast-epithelial cell interaction. Am J Respir Cell Mol Biol 5: 337-343, 1991.
59. Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, Marsh JJ. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 167: 1562-1566, 2003.
60. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secrete platelet-activating factor acetylhydrolase. J Biol Chem 265: 9682-9687, 1990.
61. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Plateletactivating factor acetylhydrolase. J Biol Chem 272: 17895-17898, 1997.
62. Suresh K, Soll RF. Lung surfactants for neonatal respiratory distress syndrome. Pediatr Drugs 4: 485-492, 2002.
63. Taeusch HW, de la Serna JB, Perez-Gil J, Alonso C, Zasadzinski JA. Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimental. Biophys J 89: 1769-1779, 2005.
64. Vondran A, Tibes U, Borowski E, Friebe W, Scheuer WV. New type II phospholipase A2 inhibitors effective in blocking an ongoing enzyme reaction: inability of manoalide and scalaradial to exert an inhibitory capacity. Prog Surg 24: 130-139, 1997.
65. Voyno-Yasenetskaya TA, Dobbs LG, Erickson SK, Hamilton RL. Low density lipoprotein-and high density lipoprotein-mediated signal transduction and exocytosis in alveolar type II cells. Proc Natl Acad Sci USA 90: 4256-4260, 1993.
66. Walther FJ, Waring AJ, Hernandez-Juviel JM, Schwan AL, Jung CL, Chang Y, Wang Z, Notter RH. Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant. PLoS ONE 2: e1039, 2007.
67. Wang Z, Schwan AL, Lairson LL, O'Donnell JS, Byrne GF, Foye A, Holm BA, Notter RH. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine. Am J Physiol Lung Cell Mol Physiol 285: L550-L559, 2003.
68. Yukitake K, Brown CL, Schlueter MA, Clements JA, Hawgood S. Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 37: 21-25, 1995.
69. Zasadzinski JA, Stenger PC, Shier I, Dhar P. Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability. Biochim Biophys Acta 1798: 801-828, 2010.
70. Zuo YY, Alolabi H, Shafiei A, Kang N, Policova Z, Cox PN, Acosta E, Hair ML, Neumann AW. Chitosan enhances the in vitro surface activity of dilute lung surfactant preparations and resists albumin-induced inactivation. Pediatr Res 60: 125-130, 2006.
71. Zuo YY, Tadayyon SM, Keating E, Zhao L, Veldhuizen RAW, Petersen NO, Amrein MW, Possmayer F. Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films, II: albumin-inhibited pulmonary surfactant films and the effect of SP-A. Biophys J 95: 2779-2791, 2008.